Protagonist Therapeutics - Stock Price History | PTGX
Historical daily share price chart and data for Protagonist Therapeutics since 2021 adjusted for splits. The latest closing stock price for Protagonist Therapeutics as of October 26, 2021 is 32.42.
- The all-time high Protagonist Therapeutics stock closing price was 49.69 on September 01, 2021.
- The Protagonist Therapeutics 52-week high stock price is 50.54, which is 55.9% above the current share price.
- The Protagonist Therapeutics 52-week low stock price is 12.80, which is 60.5% below the current share price.
- The average Protagonist Therapeutics stock price for the last 52 weeks is 31.21.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
| Protagonist Therapeutics Historical Annual Stock Price Data |
| Year |
Average Stock Price |
Year Open |
Year High |
Year Low |
Year Close |
Annual % Change |
| 2020 |
15.1514 |
6.9300 |
25.1300 |
5.4000 |
20.1600 |
185.96% |
| 2019 |
10.6231 |
6.8900 |
16.5600 |
4.6900 |
7.0500 |
4.75% |
| 2018 |
10.6858 |
21.1500 |
23.0800 |
5.9900 |
6.7300 |
-67.64% |
| 2017 |
14.5929 |
21.1800 |
21.1800 |
8.2200 |
20.8000 |
-5.41% |
| 2016 |
19.1580 |
11.7000 |
26.2400 |
10.4400 |
21.9900 |
0.00% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$1.542B |
$0.029B |
|
Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. The Company's initial lead product candidates consists of PTG-100 and PTG-200, which have the potential to transform the existing treatment paradigm for inflammatory bowel disease, a GI disease consisting primarily of ulcerative colitis and Crohn's disease; PTG-300, an injectable hepcidin mimetic. Protagonist Therapeutics, Inc. is based in Milpitas, United States.
|
